Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01332019 · ClinicalTrials.gov registry record · Phase 3

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Biogen.

Completed
Registry status
Phase 3
Development phase
1,077
Enrollment target
20
Study locations

NCT01332019 is a Phase 3 study of Relapsing Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 1,077 participants, below the 2,123-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01332019, a Phase 3 study of Relapsing Multiple Sclerosis, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 3
Development phase
1,077 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.

Conditions Studied

Relapsing Multiple Sclerosis

Interventions

  • DRUG peginterferon beta-1a

Study Locations (20)

Other

  • Research Site - Sint-Truiden
  • Research Site - Plovdiv
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Santiago
  • Research Site - Barranquilla
  • Research Site - Bogotá
  • Research Site - Zagreb

Ohio

  • Research Site - Akron
  • Research Site - Cleveland

Georgia

  • Research Site - Atlanta

Kentucky

  • Research Site - Lexington

Maryland

  • Research Site - Baltimore

North Carolina

  • Research Site - Raleigh

Tennessee

  • Research Site - Franklin

Ontario

  • Research Site - London

Trial Details

FieldValue
Enrollment Target 1,077 participants
Start Date 2011-04
Est. Completion 2015-10
Phase Phase 3

Sponsor

Biogen

334 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01332019

The ClinicalTrials.gov registry entry for NCT01332019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,077 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,123-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (49% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which peginterferon beta-1a is the first listed.

NCT01332019 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Ohio, Georgia.

Frequently Asked Questions

What is clinical trial NCT01332019 about?

NCT01332019 is a clinical study titled "Long-Term Safety and Efficacy Study of Peginterferon Beta-1a". The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term ...

What is the current status of trial NCT01332019?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,077 participants. The study started on 2011-04. Estimated completion is 2015-10.

What conditions does trial NCT01332019 study?

This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.

What interventions are being tested in trial NCT01332019?

The interventions under investigation include: peginterferon beta-1a (DRUG).

Who is sponsoring clinical trial NCT01332019?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01332019 being conducted?

This trial has 20 study locations across Georgia, Kentucky, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Multiple Sclerosis

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.